Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Change in Account Payables (2021 - 2025)

Core Scientific's Change in Account Payables history spans 5 years, with the latest figure at $28.4 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 4593.67% year-over-year to $28.4 million; the TTM value through Dec 2025 reached $10.8 million, up 187.86%, while the annual FY2025 figure was $10.8 million, 187.86% up from the prior year.
  • Change in Account Payables for Q4 2025 was $28.4 million at Core Scientific, up from -$1.2 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $86.1 million in Q4 2023 and bottomed at -$39.0 million in Q3 2021.
  • The 5-year median for Change in Account Payables is -$396000.0 (2024), against an average of $6.1 million.
  • The largest YoY upside for Change in Account Payables was 4593.67% in 2025 against a maximum downside of 674.38% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $13.1 million in 2021, then surged by 80.8% to $23.8 million in 2022, then skyrocketed by 262.56% to $86.1 million in 2023, then crashed by 100.73% to -$632000.0 in 2024, then soared by 4593.67% to $28.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Change in Account Payables are $28.4 million (Q4 2025), -$1.2 million (Q3 2025), and -$2.1 million (Q2 2025).